ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADMA ADMA Biologics

Closed Good Friday 04-17 16:00:00 EDT

21.31

+0.08

+0.38%

盘后21.31

+0.000.00%

19:54 EDT

High21.46	Low20.54	Vol2.97M
Open21.27	D1 Closing21.23	Amplitude4.33%
Mkt Cap5.06B	Tradable Cap4.96B	Total Shares237.62M
T/O62.76M	T/O Rate1.27%	Tradable Shares232.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ADMA","market":"US","secType":"STK","nameCN":"ADMA Biologics","latestPrice":21.31,"timestamp":1744920000000,"preClose":21.23,"halted":0,"volume":2965758,"hourTrading":{"tag":"盘后","latestPrice":21.31,"preClose":21.31,"latestTime":"19:54 EDT","volume":414842,"amount":8840588.7357,"timestamp":1744934089667},"delay":0,"floatShares":232866077,"shares":237615100,"eps":0.809999,"marketStatus":"Closed Good Friday","change":0.08,"latestTime":"04-17 16:00:00 EDT","open":21.27,"high":21.46,"low":20.54,"amount":62762210.105514,"amplitude":0.043335,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.809999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":21.23,"preHourTrading":{"tag":"盘前","latestPrice":21.27,"preClose":21.23,"latestTime":"09:29 EDT","volume":7792,"amount":166854.256928,"timestamp":1744896599999},"postHourTrading":{"tag":"盘后","latestPrice":21.31,"preClose":21.31,"latestTime":"19:54 EDT","volume":414842,"amount":8840588.7357,"timestamp":1744934089667},"volumeRatio":0.6298203103721165,"impliedVol":0.7485,"impliedVolPercentile":0.7331},"requestUrl":"/m/hq/s/ADMA","defaultTab":"news","newsList":[{"id":"2528770695","title":"Adma Biologics (ADMA) Beats Stock Market Upswing: What Investors Need to Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2528770695","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528770695?lang=en_us&edition=full_marsco","pubTime":"2025-04-18 05:50","pubTimestamp":1744926615,"startTime":"0","endTime":"0","summary":"Adma Biologics  closed at $21.31 in the latest trading session, marking a +0.38% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.13% for the day. Meanwhile, the Dow lost 1.33%, and the Nasdaq, a tech-heavy index, lost 0.13%.Shares of the infectious disease drug developer have appreciated by 3.01% over the course of the past month, outperforming the Medical sector's loss of 8.46% and the S&P 500's loss of 6.3%.Market participants will be closely following the financial results of Adma Biologics in its upcoming release. The company is forecasted to report an EPS of $0.16, showcasing a 100% upward movement from the corresponding quarter of the prior year. In the meantime, our current consensus estimate forecasts the revenue to be $119.1 million, indicating a 45.46% growth compared to the corresponding quarter of the prior year.Investors should also take note of any recent adjustments to analyst estimates for Adma Biologics. Recent revisions tend to re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-adma-beats-stock-215015603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","ISBC","BK4139","ADMA"],"gpt_icon":0},{"id":"2527247077","title":"DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2527247077","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527247077?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 20:52","pubTimestamp":1744807920,"startTime":"0","endTime":"0","summary":"Shares of Precision BioSciences DTIL rallied 23.8% on Tuesday after the company’s announcement that the FDA has granted Fast Track designation to PBGENE-HBV. This is DTIL’s lead, fully owned in vivo gene editing program aimed at curing chronic hepatitis B by eliminating cccDNA — the primary source of replicating hepatitis B virus  — and inactivating integrated HBV DNA in liver cells .The FDA’s Fast Track designation is intended to speed up the development and review of drugs that treat serious conditions and fulfill unmet medical needs. It offers benefits, such as more frequent FDA interactions, rolling submission of marketing applications, and potential eligibility for Priority Review if certain conditions are met.According to Precision BioSciences, PBGENE-HBV is the first and only gene editing program with this unique mechanism of action to enter the clinical stage as a potential cure.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dtil-gets-fdas-fast-track-125200444.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BAYRY","BK4007","BK4139","DVAX","ADMA","IE00B5TLWC47.USD","IE00BFXG0V08.USD","IE00BYQQ9H92.USD","BK4585","FAST","BK4567","BK4104","BK4588","DTIL"],"gpt_icon":0},{"id":"2527294389","title":"Why ADMA Biologics, Inc. (ADMA) Skyrocketed On Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527294389","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527294389?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 18:45","pubTimestamp":1744800356,"startTime":"0","endTime":"0","summary":"A muted trading persisted on the stock market on Tuesday, with major indices ending in the red, recording minimal losses while digesting President Donald Trump’s tariff policies.The Dow Jones declined by 0.38 percent, the S&P 500 dipped by 0.17 percent, while the tech-heavy Nasdaq dipped by 0.05 percent.Ten companies bucked a broader market pessimism, booking modest gains during the session. In this article, we have identified the reasons behind their gains.To come up with the list, we only considered the stocks with $2 billion market capitalization and $5 million trading volume.An independent distributor in their pharmacy with a range of biopharmaceutical products on display.ADMA Biologics rallied for a third straight day on Tuesday, adding 5.93 percent to end at $22.15 as investor sentiment was buoyed by its business optimism, saying it sees only minimal to no impact from the ongoing trade tensions globally.“The tariffs that have been implemented on foreign goods, services, and manuf","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-adma-biologics-inc-adma-104556120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"2527290404","title":"VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2527290404","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527290404?lang=en_us&edition=full_marsco","pubTime":"2025-04-16 00:27","pubTimestamp":1744734420,"startTime":"0","endTime":"0","summary":"Shares of Verve Therapeutics VERV surged 26.4% on Monday and continue to soar today after the company announced positive initial datafrom an early-stage study of its investigational candidate, VERVE-102, which is being developed for reducing cholesterol levels. VERVE-102 is a novel,in vivo, investigational base editing medicine.The data readout includes 14 patients from the first three cohorts who received doses of VERVE-102 at 0.3 mg/kg, 0.45 mg/kg, or 0.6 mg/kg, respectively, with each participant having at least 28 days of follow-up as of the data cutoff date of March 13, 2025.More on VERV’s Phase I Cholesterol Drug Study Data. Verve Therapeutics reported that a single infusion of VERVE-102 resulted in dose-dependent reductions in blood PCSK9 protein levels and LDL-C in the Heart-2 study, with an average LDL-C decrease of 53% and a maximum reduction of 69% observed among four participants in the 0.6 mg/kg dose cohort.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verv-stock-soars-superior-efficacy-162700742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GB00BDT5M118.USD","LU0640476718.USD","LU1035775433.USD","LU1093756325.SGD","LU2089984988.USD","LU0122379950.USD","LLY","LU2360106947.USD","SGXZ81514606.USD","LU2471134796.USD","BAYRY","LU0094547139.USD","LU1023059063.AUD","LU1868836757.USD","LU2357305700.SGD","VERV","LU0820561909.HKD","LU2471134879.HKD","LU1720051108.HKD","SG9999015978.USD","IE00BK4W5L77.USD","IE00BK4W5M84.HKD","LU2237443549.SGD","IE0009355771.USD","SG9999001176.SGD","LU0238689110.USD","LU0198837287.USD","BK4585","LU1623119135.USD","LU2063271972.USD","LU1712237335.SGD","LU1127390331.HKD","LU2491050154.USD","LU1720051017.SGD","ADMA","LU0106261372.USD","LU0672654240.SGD","BK4588","LU0943347566.SGD","LU1093756168.USD","LU0079474960.USD","SG9999015986.USD","LU2023250504.SGD","LU0320765059.SGD","LU1551013425.SGD","LU2324357040.USD","LU2491050071.SGD","LU0058720904.USD","LU2468319806.SGD","LU1280957306.USD"],"gpt_icon":1},{"id":"2527015440","title":"Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag","url":"https://stock-news.laohu8.com/highlight/detail?id=2527015440","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527015440?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 22:42","pubTimestamp":1744728120,"startTime":"0","endTime":"0","summary":"Fate Therapeutics FATE recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy  designation to its investigational pipeline candidate FT819 for the treatment of active moderate to severe systemic lupus erythematosus , including lupus nephritis.The RMAT designation provides the candidate with increased opportunities to meet FDA officials, as well as arrange early meetings to discuss potential surrogate or intermediate endpoints. It opens up early interactions between the FDA and sponsors to facilitate accelerated approval and potential priority review of a product’s biologics license application.FT819 is an off-the-shelf, iPSC-derived CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking.The latest RMAT designation by the FDA underlines the potential of FT819 to address an area of significant unmet medical needs.Year to date, shares of Fate Therapeutics have plunged 44% comp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-lupus-candidate-ft819-144200510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA","BK4532","BK4533","IE00BN0W2V16.EUR","JAZZ","IE00BN0W2W23.USD","LU0823416689.USD","SLE","IE00BN0W2T93.GBP","LU0320765992.SGD","FATE","LU0889565916.HKD","BK4077","KRYS","LU0109394709.USD","BK4007","BK4139"],"gpt_icon":0},{"id":"2527444905","title":"Are Medical Stocks Lagging  ADMA Biologics (ADMA) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527444905","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527444905?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 21:40","pubTimestamp":1744724412,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adma Biologics  been one of those stocks this year?By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Adma Biologics is a member of the Medical sector. This group includes 1003 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Adma Biologics is currently sporting a Zacks Rank of #2 .Another stock in the Medical sector, Agilon Health , has outperformed th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-adma-biologics-134012510.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA","AGL","BK4539","BK4196","BK4139"],"gpt_icon":0},{"id":"2527449094","title":"Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average","url":"https://stock-news.laohu8.com/highlight/detail?id=2527449094","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527449094?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 21:35","pubTimestamp":1744724102,"startTime":"0","endTime":"0","summary":"Adma Biologics  is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ADMA crossed above the 20-day moving average, suggesting a short-term bullish trend.The 20-day simple moving average is a popular investing tool. Traders like this SMA because it offers a look back at a stock's price over a shorter period and helps smooth out price fluctuations. The 20-day can also show more trend reversal signals than longer-term moving averages.The 20-day moving average can show signals that are similar to other SMAs as well. If a stock's price is moving above the 20-day, the trend is considered positive. When the price falls below the moving average, it can signal a downward trend.Over the past four weeks, ADMA has gained 12%. The company is currently ranked a Zacks Rank #2 , another strong indication the stock could move even higher.The bullish case solidifies once investors consider ADMA's positive earnings estimate revisions. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-adma-just-overtook-133502885.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ADMA"],"gpt_icon":0},{"id":"2527449519","title":"Ironwood Shares Tank on Regulatory Update for Apraglutide","url":"https://stock-news.laohu8.com/highlight/detail?id=2527449519","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527449519?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 21:18","pubTimestamp":1744723080,"startTime":"0","endTime":"0","summary":"Shares of Ironwood Pharmaceuticals IRWD plunged 31.5% yesterday after it announced regulatory updates on the next-generation GLP-2 analog, apraglutide, which is being developed for treating short bowel syndrome  with intestinal failure .Following the recent discussion with the FDA, management noted that a confirmatory phase III study will be required to seek approval of apraglutide for patients with SBS-IF and dependent on parenteral support.Simultaneously, IRWD is looking to explore alternatives aimed at maximizing shareholder value.Ironwoodinitiated the rolling new drug application submission to the FDA for apraglutide to treat SBS patients who are dependent on parenteral support in January 2025.However, following the latest discussion with the FDA, a confirmatory phase III study will now be required for apraglutide approval. This, in turn, is likely to extend the timeline for the NDA filing completion and also potentially delay the approval for apraglutide.In the past 60 days, estim","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ironwood-shares-tank-regulatory-apraglutide-131800007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0823416689.USD","LU0109394709.USD","BK4533","IRWD","IE00BN0W2T93.GBP","LU0320765992.SGD","IE00BN0W2W23.USD","ADMA","BK4139","BK4532","JAZZ","IE00BN0W2V16.EUR","BK4007","LU0889565916.HKD","KRYS"],"gpt_icon":0},{"id":"2527445260","title":"Adma Biologics (ADMA) Moves 7.8% Higher: Will This Strength Last?","url":"https://stock-news.laohu8.com/highlight/detail?id=2527445260","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527445260?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 20:59","pubTimestamp":1744721940,"startTime":"0","endTime":"0","summary":"Adma Biologics  shares rallied 7.8% in the last trading session to close at $20.91. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5.3% gain over the past four weeks.Strong fundamentals, buoyed by broader market optimism, drove this rally for ADMA Biologics.This infectious disease drug developer is expected to post quarterly earnings of $0.16 per share in its upcoming report, which represents a year-over-year change of +100%. Revenues are expected to be $119.1 million, up 45.5% from the year-ago quarter.Adma Biologics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Blueprint Medicines , finished the last trading session 2.1% higher at $82.53. BPMC has returned -9.8% over the past month.For Blueprint Medicines , the consensus EPS estimate for the upcoming report has changed +15.4% over the past month to -$0.41. This represents a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-adma-moves-7-125900737.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BPMC","BK4139","ADMA","BK4505","LU0053671581.USD"],"gpt_icon":0},{"id":"2526761082","title":"NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat","url":"https://stock-news.laohu8.com/highlight/detail?id=2526761082","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526761082?lang=en_us&edition=full_marsco","pubTime":"2025-04-12 01:17","pubTimestamp":1744391820,"startTime":"0","endTime":"0","summary":"Swiss pharma giant Novartis NVS announced a planned $23 billion investment over five years in U.S.-based infrastructure.Backed by this investment, the company intends to manufacture all key drugs for its U.S. patients in the country.NVS' decision to expand its current manufacturing, research and technology presence across the country follows President Trump's announcement of tariffs on pharmaceutical imports.The company's shares are up in pre-market. Novartis’ shares have risen 8.7% year to date against the industry’s decline of 8.2%.NVS expanded its manufacturing and R&D presence in the country by investing in 10 facilities, including seven brand-new ones.Over the next five years, Novartis will establish a biomedical research innovation hub in San Diego, CA, its second global R&D hub in the United States. This is expected to open during 2028-2029.These investments will ensure Novartis has manufacturing capacity in the United States for all its core technology platforms, including smal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvs-plans-invest-23b-us-171700008.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","LU0208291251.USD","BK4007","ADMA","LU0211331839.USD","LU0320765489.SGD","LU0070302665.USD","IE00B2B36J28.USD","IE0002141913.USD","BK4139","BK4578","BAYRY","BK4588","IE00B4R5TH58.HKD","BK4532","IE00BFTCPJ56.SGD","NVS","IE00BJT1NW94.SGD","IE0009355771.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2526233615","title":"Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2526233615","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526233615?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 23:49","pubTimestamp":1744386540,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics Holdings Inc. ARCT announced that the FDA has granted a Fast Track designation to its self-amplifying mRNA  vaccine candidate, ARCT-2304, for active immunization to protect against the influenza A H5N1 virus.The Fast Track designation from the FDA facilitates rapid development and expedites the review of vaccines that are being developed to treat serious conditions and have the potential to address unmet medical needs.The Fast Track tag is likely to expedite the development path for ARCT-2304 and help in faster regulatory filing for the vaccine in the United States.In November 2024, the FDA cleared the investigational new drug  application to begin clinical studies on the sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza disease caused by the H5N1 virus.Arcturus developed the first sa-mRNA COVID-19 vaccine, Kostaive. The company has a collaboration agreement with renowned vaccine company CSL Seqirus for making innovative m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcturus-gets-fdas-fast-track-154900033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","IE00BN0W2W23.USD","BK4548","BK4535","FAST","IE00BN0W2T93.GBP","BK4585","LU0109394709.USD","BK4551","ARCT","BK4139","BK4533","BK4588","CF","JAZZ","IE00BN0W2V16.EUR","BK4007","BK4093","LU0320765992.SGD","ADMA","LU0823416689.USD","BNTX","BK4568","KRYS","LU0889565916.HKD"],"gpt_icon":0},{"id":"2526511532","title":"PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose","url":"https://stock-news.laohu8.com/highlight/detail?id=2526511532","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526511532?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 22:53","pubTimestamp":1744296780,"startTime":"0","endTime":"0","summary":"Shares of Phio Pharmaceuticals PHIO rallied 52.5% on Wednesday after the company announced that the Safety Monitoring Committee  has recommended dose escalation in an early-stage study of the company’s investigational skin cancer candidate, PH-762.PH-762 is Phio Pharmaceuticals’ lead and only clinical-stage candidate, which is being developed leveraging its proprietary IntasylsiRNA gene silencing technology to eliminate cancer. The phase Ib dose escalation study is evaluating the safety and tolerability of neoadjuvant use of intratumoral PH-762 for cutaneous squamous cell carcinoma, melanoma or Merkel cell carcinoma.The SMC’s decision allowing escalation to the next dose concentration was based on the favorable safety profile of the drug observed in the third cohort of the phase Ib study, which enrolled three patients with cutaneous squamous cell carcinoma. In these patients, injections were well tolerated, with no serious adverse events or dose-limiting toxicities. Pathology results a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/phio-stock-soars-safety-panel-145300505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BAYRY","SMC","ADMA","BK4144","DVAX","PHIO","BK4139"],"gpt_icon":0},{"id":"2526846907","title":"PCRX Stock Soars on Exparel Patent Settlement With Generic Players","url":"https://stock-news.laohu8.com/highlight/detail?id=2526846907","media":"Zacks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526846907?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 23:29","pubTimestamp":1744126140,"startTime":"0","endTime":"0","summary":"Shares of Pacira BioSciences PCRX are rising today after the company announced that it has entered into a settlement agreement with Fresenius, Jiangsu Hengrui Pharmaceuticals and eVenus Pharmaceuticals Laboratories, related to patents for Exparel .Following the settlement, which resolves the patent litigation brought by Pacira BioSciences against the companies, Consent Judgments will be filed in multiple courts, preventing Fresenius, like the others, from marketing generic bupivacaine liposome injectable suspension before the relevant patents expire, except as outlined in the agreement.Exparel is PCRX’s flagship pain-management product,which was initially launched in 2012. The drug is indicated for postsurgical local analgesia in patients aged six years and older. It is also indicated for regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal.Year to date, shares of Pacira Bi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pcrx-stock-soars-exparel-patent-152900546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA","PCRX","BAYRY","BK4139","DVAX","BK4007"],"gpt_icon":0},{"id":"2526846182","title":"RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2526846182","media":"Zacks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526846182?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 23:21","pubTimestamp":1744125660,"startTime":"0","endTime":"0","summary":"Shares of Rhythm Pharmaceuticals RYTM rallied 17.1% on Monday after the company announced that it has met the primary endpoint in a late-stage study of its candidate, setmelanotide, for treating acquired hypothalamic obesity.RYTM’s setmelanotide is an MC4R agonist.Per the data readout, the phase III TRANSCENDstudy met its primary endpoint with a statistically significant and clinically meaningful reduction in body mass index  with setmelanotide in adult and pediatric patients compared to placebo. It was observed that all patients with acquired hypothalamic obesity who underwent setmelanotide therapy experienced an average BMI reduction of 16.5% over 52 weeks, whereas those on placebo saw a 3.3% increase.Please note that setmelanotide is already approved as Imcivree in the United States and EU for chronic weight management in adult and pediatric patients aged two years and older with certain genetic conditions. The eligible patient population includes those with monogenic or syndromic o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rytm-stock-rises-17-meeting-152100157.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BAYRY","RYTM","BK4157","BMI","DVAX","BK4139","ADMA","BK4585","BK4007"],"gpt_icon":0},{"id":"2525812701","title":"Viatris to Pay $335 Million for Settlement of Opioid-Related Claims","url":"https://stock-news.laohu8.com/highlight/detail?id=2525812701","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525812701?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 21:56","pubTimestamp":1744120560,"startTime":"0","endTime":"0","summary":"Viatris, Inc. VTRS announced that it has reached a nationwide settlement framework to resolve opioid-related claims by states, local governments, and tribes against it and certain of its subsidiaries.Per the terms of the settlement agreement, Viatris would pay up to a maximum of $335 million to all the above-mentioned parties. This sum consists of annual payments of approximately $27.5-$40 million to each party over a period of nine years to help support state and local efforts to address opioid-related issues.However, Viatris stated that the settlement is in no way an admission of wrongdoing or liability.VTRS’ share price has plunged 38.1% year to date compared with the industry’s 4.6% decline.Viatris accrued approximately $270 million as of Dec. 31, 2024, in connection with the possible resolution of certain of these matters, which is included in other current liabilities in the consolidated balance sheets.Viatris was formed through the merger of the erstwhile Mylan and Pfizer’s PFE ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viatris-pay-335-million-settlement-135600855.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999013999.USD","LU1894683264.USD","LU0321505868.SGD","IE0002270589.USD","BK4581","IE000M9KFDE8.USD","BK4592","IE00BLSP4452.SGD","LU0058720904.USD","SG9999002224.SGD","BMRN","SG9999002232.USD","ADMA","LU1883839398.USD","IE00BLSP4239.USD","BK4568","LU0306806265.USD","LU1066051498.USD","SG9999003800.SGD","BK4139","LU0225284248.USD","LU0122379950.USD","BK4550","LU2087621335.USD","LU1057294990.SGD","LU0868494617.USD","BK4534","IE00B19Z3581.USD","LU1894683348.USD","LU0456855351.SGD","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","BK4585","LU0321505439.SGD","LU0234572021.USD","SG9999011175.SGD","BK4533","BK4007","LU1839511570.USD","BK4599","BK4588","LU0306807586.USD","IE00BBT3K403.USD","SG9999001176.USD","LU1066053197.SGD","LU0985481810.HKD","LU0170899867.USD","VTRS"],"gpt_icon":1},{"id":"2525207390","title":"5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2525207390","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525207390?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 01:22","pubTimestamp":1744046520,"startTime":"0","endTime":"0","summary":"The current macro environment appears grim, given the uncertainty around the global trade war, along with ongoing geopolitical tension. While 2025 started on an encouraging note and strong quarterly results buoyed investor optimism, a likely overall slowdown does not bode well. Nonetheless, given the continuous need for innovative medical treatments, irrespective of the state of the economy, the dynamic biotech industry will continue to grab investors’ interest despite the inherent volatility and uncertain macroeconomic environment.M&A activity is likely to accelerate in 2025 under the Trump administration and expected deregulation. Pharma and biotech industry leaders consistently seek to expand their product portfolios and pipelines through strategic collaborations and acquisitions. While oncology and immuno-oncology companies have always been at the top of acquisition targets, the lucrative obesity sector and gene-editing space are in spotlight as of now.Biotech companies like Gilead","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/5-biotech-stocks-worth-adding-172200110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2089984988.USD","KRYS","SH","LU1585245621.USD","BK4578","LU1066051498.USD","IE00B3T34201.USD","BK4139","BK4581","ADMA","BK4588","LU0320765992.SGD","BMRN","LU0058720904.USD","BK4504","IE00BZ1G4Q59.USD","IVV","IE0002270589.USD","LU1839511570.USD","LU2065170008.USD","ESmain","LU2065171311.SGD","SDS","SPY","IE00B19Z3B42.SGD","LU0234570918.USD","LU2065169927.USD","GILD","LU2468319806.SGD","BK4585","VOO","OEF",".SPX","OEX","LU2065171402.SGD","BK4550","FOLD","BK4559","IE00BKVL7J92.USD","BK4532","LU1571399168.USD","LU0889565916.HKD","BK4583","LU0289739699.SGD","BK4534","SSO","LU1066053197.SGD"],"gpt_icon":1},{"id":"2525023690","title":"Does Adma Biologics (ADMA) Have the Potential to Rally 51.75% as Wall Street Analysts Expect?","url":"https://stock-news.laohu8.com/highlight/detail?id=2525023690","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525023690?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 21:55","pubTimestamp":1744034103,"startTime":"0","endTime":"0","summary":"Adma Biologics  closed the last trading session at $18.01, gaining 5.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $27.33 indicates a 51.8% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $4.04. While the lowest estimate of $25 indicates a 38.8% increase from the current price level, the most optimistic analyst expects the stock to surge 77.7% to reach $32. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/does-adma-biologics-adma-potential-135503644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADMA","BK4139"],"gpt_icon":0},{"id":"2525048270","title":"Sector Update: Health Care","url":"https://stock-news.laohu8.com/highlight/detail?id=2525048270","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525048270?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 20:54","pubTimestamp":1744030459,"startTime":"0","endTime":"0","summary":"Health care stocks leaned lower premarket Monday with the Health Care Select Sector SPDR Fund  and iShares Biotechnology ETF  down 2.1% recently.ADMA Biologics  said it doesn't expect the latest US tariffs on foreign goods and services to have any impact on its supply chain or production operations. Shares of ADMA Biologics fell past 4% pre-bell.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4588","BK4139","IBB","ADMA","XLV","BK4581"],"gpt_icon":0},{"id":"2525230014","title":"BRIEF-Adma Biologics - Tariffs Expected To Have No Impact On Adma's Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2525230014","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525230014?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 19:40","pubTimestamp":1744026039,"startTime":"0","endTime":"0","summary":"BRIEF-Adma Biologics - Tariffs Expected To Have No Impact On Adma's OperationsApril 7 (Reuters) - ADMA Biologics Inc ADMA.O:ADMA BIOLOGICS STATEMENT ON TARIFFSADMA BIOLOGICS INC - TARIFFS EXPECTED TO ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nFWN3QL04N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADMA","BK4139"],"gpt_icon":0},{"id":"2525969014","title":"ADMA Biologics Says Tariffs Not Likely to Impact Supply Chain, Production Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2525969014","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525969014?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 19:34","pubTimestamp":1744025660,"startTime":"0","endTime":"0","summary":"ADMA Biologics  said Monday it doesn't expect the latest US tariffs on foreign goods and services to have any impact on its supply chain or production operations.The company's manufacturing operations, end-market sales, and customer engagements are all conducted exclusively within the US, Chief Executive Adam Grossman said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ADMA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.admabiologics.com","stockEarnings":[{"period":"1week","weight":0.1408},{"period":"1month","weight":0.139},{"period":"3month","weight":0.3302},{"period":"6month","weight":0.3504},{"period":"1year","weight":2.5281},{"period":"ytd","weight":0.2426}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.027611},{"month":2,"riseRate":0.545455,"avgChangeRate":-0.01132},{"month":3,"riseRate":0.636364,"avgChangeRate":0.108134},{"month":4,"riseRate":0.636364,"avgChangeRate":0.013397},{"month":5,"riseRate":0.7,"avgChangeRate":0.076004},{"month":6,"riseRate":0.2,"avgChangeRate":-0.053782},{"month":7,"riseRate":0.7,"avgChangeRate":0.113035},{"month":8,"riseRate":0.3,"avgChangeRate":0.011317},{"month":9,"riseRate":0.2,"avgChangeRate":-0.020319},{"month":10,"riseRate":0.4,"avgChangeRate":-0.051308},{"month":11,"riseRate":0.6,"avgChangeRate":0.079185},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.06159}],"exchange":"NASDAQ","name":"ADMA Biologics","nameEN":"ADMA Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ADMA Biologics,ADMA,ADMA Biologics股票,ADMA Biologics股票老虎,ADMA Biologics股票老虎国际,ADMA Biologics行情,ADMA Biologics股票行情,ADMA Biologics股价,ADMA Biologics股市,ADMA Biologics股票价格,ADMA Biologics股票交易,ADMA Biologics股票购买,ADMA Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction